You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

April 8, 2020

Laos Issues COVID-19 Regulations for Freight, Insurance, Mineral Processing, Hydropower, and Healthcare Industries

Subscribe to Updates

Cross-Border Transportation of Goods

The National Taskforce Committee for COVID-19 Prevention and Control has issued Guideline No. 020, Regarding Prime Minister’s Order No.02/PM, dated April 2, 2020, which includes directives aimed at the freight sector. The transportation of goods is one of the few operations that is still permitted to cross the Lao border, although this is subject to the following regulations:

  • The importation of goods by vehicles is authorized up to the loading point closest to the port of entry. Once the goods have been unloaded, the vehicle must depart immediately. Before entering Laos the driver must fill out a health form and undergo an examination, as recommended by the National Taskforce Committee for COVID-19 Prevention and Control.
  • For the transportation of goods that transit through Laos before being exported to a third country, vehicles can proceed to the loading point in Laos and onward to their destination. If it is necessary to use a vehicle from the country of origin to reach the destination, the vehicle must be sprayed with a disinfectant in accordance with the specified rules. Foreign drivers are also prohibited, so the driver must be a Lao national.

Insurance Operations

On March 31, 2020, the Department of State Enterprise Investment Management and Insurance, which is under the Ministry of Finance, issued Notification No. 0338, which provides the following measures:

  • Deferment of the deadline for submission of insurance company financial reports and other reporting duties relating to the operation of insurance businesses for the year 2019. The new submission deadline is April 30, 2020.
  • Requirement for life insurance and health insurance policies that have already been sold to also cover COVID-19-related symptoms, in accordance with the amount and duration of coverage agreed upon in the contract.
  • Requirement for all insurance companies to devise a plan to form teams of employees to work in their offices from April 1 to April 19, 2020, and to support other employees to work remotely. Alternatively, companies can devise a specific schedule for each employee to come to work on an alternating basis, in order to prevent the spread of the COVID-19. Insurance companies are also requested to ensure they can receive claims while the COVID-19 outbreak measures are in place.

Factories that Process Minerals and Hydropower Plants under Construction

On April 5, 2020, the Ministry of Mines and Energy issued Notification 0432/MEM, which orders hydropower plant construction projects and factories involved in exploration for and processing of minerals to suspend their activities from April 1 to April 19.

Until April 19, these operations are required to proceed as follows:

  • Manage their staff and personnel who are currently renting and staying in accommodation within the factory, and follow measures issued by the government. Employees and personnel should not leave the factory premises, or their accommodations, if it is not necessary (a phrase that is not yet defined). Employees and personnel must be prohibited from traveling to local places where there is a risk of contracting the virus.
  • Disseminate information about COVID-19 to employees and personnel on-site in order to prevent and combat the spread of the virus, in accordance with recommendations issued by the local authorities. Any employee who displays symptoms of the virus should be separated from the other employees, and the supervisor should immediately contact the emergency number (166 or 020-5406-6777) in order to implement the recommendations issued by the National Task Force.
  • Ensure that social distancing of two meters is strictly observed by all employees, provide masks, and ensure that soap is available for washing hands, or disinfectant is provided to kill the virus, in accordance with the recommendations of the National Task Force.
  • Disinfect the premises, including production sites, canteens, and accommodations, along with other areas where there is a risk of the virus spreading.

Facilities that have been closed and adversely impacted by COVID-19 should report the impact to the Ministry of Energy and Mines, and the related authorities, as indicated in Prime Minister’s Order No. 06/PM, dated March 29, 2020. In addition, the ministry welcomes comments regarding this notification from stakeholders and from the public and private sectors.

Private Hospitals and Clinics Prohibited from Treating COVID-19

Out of a concern about some private caregiving facilities in the country being inadequately equipped to handle the epidemic, on April 2, 2020, the Ministry of Health issued Notification 0413/MOH, ordering private hospitals and treatment facilities not to attempt treatment of COVID-19 patients (with limited exceptions for international-standard private hospitals). 

This notification followed the issuance of previous measures seemingly announcing the closure of private hospitals and private treatment centers. Together, however, these regulations mean that  specialized clinics and private hospitals can provide their usual medical services, but they are not allowed to attempt treatment of COVID-19 patients; if a case of COVID-19 is suspected, they should call the emergency hotline immediately.

For more details on these measures, or on any aspect of Laos’ response to the COVID-19 pandemic, please contact Dino Santaniello at [email protected].

Related Professionals

Industries

Aviation

Energy

Insurance

Life Sciences

Practices

Corporate/M&A

Regulatory Affairs

Location

RELATED INSIGHTS​ 

June 24, 2026
Patent enablement requirements are provided under Article 102 of Vietnam’s Law on Intellectual Property (IP Law). In particular, a patent specification must “fully and clearly disclose the nature of the invention to such an extent that, based on the specification, a person having ordinary skill in the relevant art can implement the invention.” In pharmaceutical and biotechnology patents, this requirement is more complicated and subject to more rigorous assessment. The Patent Examination Guidelines (Guidelines) of the Intellectual Property Office of Vietnam (IP Office) were amended in March 2026 to introduce Annexes III and IV for the pharmaceutical and biotechnology sectors, in which Annex III provides detailed guidelines on the assessment of specification requirements. These amendments were made under a project for strengthening capacity in industrial property examination between the Japan International Cooperation Agency (JICA) and the IP Office. Annex III provides detailed instructions on how examiners assess enablement in a pharmaceutical or biotechnology application, and offers examples of acceptable and unacceptable descriptions with regard to the enablement aspect. Enablement Requirements in Pharma and Biotech Patents Article 12.7 of Circular 10/2026/TT-BKHCN (Circular 10) adds to the requirements of Article 102 of the IP Law that the description must demonstrate the novelty, inventive step, and industrial applicability of the technical solution. For pharmaceutical composition subject matters, Article 12.9 of Circular 10 sets out that the description must present the results of clinical trials and/or the pharmacological effects of the claimed pharmaceutical composition, and must include at least the following information: Substance/mixture used. Testing method (system) employed. Information on the test results. Correlation between the pharmacological effects obtained from the tests and the application of the pharmaceutical product in the prevention, diagnosis, and treatment of diseases. The Guidelines note that pharmacological study results should be presented in a quantified manner, and pharmacological
Read More
June 19, 2026
For the first time, Thailand’s Food and Drug Administration (FDA) has published a consolidated list identifying all substances that have successfully passed its novel food safety evaluation process. The list is a step forward in regulatory transparency, but it also highlights a feature of the Thai regime that food companies often overlook: each approval is tied exclusively to the company that applied for it. A substance’s appearance on the list does not give other companies the green light to use it. This article examines the structure of Thailand’s novel food approval framework, the implications of applicant exclusivity, and the strategic choices it requires of food companies looking to bring novel ingredients to the Thai market. Thai FDA Food Safety Evaluation Framework Notification No. 376 of the Ministry of Public Health requires novel food substances to undergo a food safety assessment, with an exemption only for novel foods manufactured exclusively for export. The framework also encompasses “foods that do not qualify as novel foods” but which present characteristics warranting a safety evaluation, such as differing quality standards, increased serving sizes, or applications in specific food categories, where such changes affect consumption levels, nutritional value, or consumer safety. The recently published list of foods that passed the safety evaluation by the Thai FDA is structured by substance category and identifies the approved company (domestic manufacturer or importer), country of origin, substance name and trade name, approved purpose of use, and date of the Thai FDA’s approval notification certificate. A notable feature of Thailand’s novel food regime is that the approval result is tied exclusively to the company that submitted the application. Publication of the consolidated list does not constitute a general authorization to use the approved substances. The Thai FDA’s approval certificate specifies the approved conditions of use and the requirements
Read More
June 17, 2026
Thailand’s new labeling requirements for medical devices, which include for the first time a unique device identification (UDI) requirement for software as a medical device (SaMD), take effect on June 20, 2026. The Notification of the Ministry of Public Health regarding Criteria, Methods, and Conditions on Labeling and Instructions for Use for Medical Devices 2025, which replaces a similar notification from 2020, was published in the Government Gazette on December 22, 2025. To ensure clarity, modernity, and patient safety, the regulation requires domestic manufacturers and importers to provide labels and instructions for use (IFU) that are clearly legible, complete, and free of false or misleading claims. It also permits IFU to be provided in electronic format, such as via QR codes, websites, or other digital channels—directly relevant to SaMD, where physical labels are impractical and electronic presentation is the natural medium. The notification distinguishes two categories for labeling language. Home-use medical devices (for lay users outside healthcare facilities) must have labels and IFU in Thai. Professional-use medical devices may display labels and documentation in either Thai or English. This distinction is significant for SaMD developers: software intended for clinical professionals may use English-language interfaces and IFU, while consumer-facing health applications must provide Thai-language content. Labeling and UDI Requirements Labels and IFU must include, at a minimum: Product name and intended purpose Quantity or volume Name and address of domestic manufacturer or importer Thai FDA approval number Lot, version, or serial number Manufacturing date and expiry date For SaMD, the version number requirement is particularly relevant. The regulation also mandates display of a UDI code for SaMD in risk category 2 (moderate-risk), category 3 (moderate- to high-risk), and category 4 (high-risk), according to Thailand’s medical device risk classification system (which complies with the ASEAN Medical Device Directive and the EU
Read More
June 5, 2026
On May 25, 2026, Vietnam’s Ministry of Health issued Circular No. 16/2026/TT-BYT governing free-of-charge medicine support programs for medical establishments (Circular 16). Circular 16 will take effect on July 10, 2026, replacing Circular No. 31/2018/TT-BYT, which currently regulates the same subject matter. Circular 16 introduces several significant changes compared to the existing legal framework. Removal of Prior Approval Requirement Under the current regulations, free-of-charge medicine support programs are divided into two categories: (1) entirely free-of-charge provision of medicines for all types of drugs and (2) partially free-of-charge provision applicable only to brand-name drugs under patent protection or drugs whose generic products with identical active ingredients and dosage forms are available in Vietnam. Under the current regulations, partially free-of-charge programs are subject to mandatory registration with the competent authority, while entirely free-of-charge programs could be implemented without prior approval. A key reform under Circular 16 is that it stipulates only entirely free-of-charge medicine support programs applicable to all types of medicines, thereby eliminating the partially free-of-charge category. In addition, free-of-charge medicine support programs may be carried out solely based on a written agreement between the pharmaceutical company and the medical establishment, without any requirement for prior approval from competent authorities prior to implementation. Written Agreement Requirements Circular 16 requires the pharmaceutical company and medical establishment to enter into a written agreement in accordance with a prescribed template. This agreement must include the following compulsory information: Information on the supported medicines Form of support (entirely free-of-charge provision to patients) Quantity of medicines provided Target patient groups and applicable indications Duration of the program Rights and obligations of each party Transitional provisions on the protection of patients’ rights upon completion of the program The agreement may contain other contents as agreed by the parties, provided that these do not contradict applicable laws.
Read More